Krystal Biotech, Inc. (KRYS): Price and Financial Metrics


Krystal Biotech, Inc. (KRYS): $74.72

-0.01 (-0.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KRYS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KRYS Stock Price Chart Interactive Chart >

Price chart for KRYS

KRYS Price/Volume Stats

Current price $74.72 52-week high $102.99
Prev. close $74.73 52-week low $38.86
Day low $74.15 Volume 203,005
Day high $75.60 Avg. volume 204,904
50-day MA $60.35 Dividend yield N/A
200-day MA $60.92 Market Cap 1.92B

Krystal Biotech, Inc. (KRYS) Company Bio


Krystal Biotech Inc. develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The company’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. The company was founded in 2015 and is based in Pittsburgh, Pennsylvania.


KRYS Latest News Stream


Event/Time News Detail
Loading, please wait...

KRYS Latest Social Stream


Loading social stream, please wait...

View Full KRYS Social Stream

Latest KRYS News From Around the Web

Below are the latest news stories about Krystal Biotech Inc that investors may wish to consider to help them evaluate KRYS as an investment opportunity.

Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference

PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference, which is taking place virtually March 7-9, 2022. Details are as follows: Fireside Chat Date:Monday, March 7, 2022Fireside Chat Time:2:50-3:20 p.m. ESTWebcast link:https://wsw.com/webcast/cowen108/krys/2056

Yahoo | February 24, 2022

Is Krystal Biotech Inc. (NASDAQ: KRYS) Still A Loss Stock Despite Being Down -12.99% YTD?

During the last session, Krystal Biotech Inc. (NASDAQ:KRYS)s traded shares were 0.3 million, with the beta value of the company hitting 0.99. At the end of the trading day, the stocks price was $60.86, reflecting an intraday loss of -6.84% or -$4.47. The 52-week high for the KRYS share is $102.99, that puts it down Is Krystal Biotech Inc. (NASDAQ: KRYS) Still A Loss Stock Despite Being Down -12.99% YTD? Read More »

Marketing Sentinel | February 19, 2022

Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ...

Investment company Act Capital Management, Llc (Current Portfolio) buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, AirSculpt Technologies Inc, enVVeno Medical Corp, sells , Upstart Holdings Inc, Affirm Holdings Inc, Nektar Therapeutics, Nuance Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Act Capital Management, Llc.

Yahoo | February 3, 2022

2 Biotech Stocks That Could Skyrocket This Year

Investing in small-cap, clinical-stage biotech stocks can be a double-edged sword. With that in mind, let's turn to two biotech stocks that could soar (and provide above-average returns to patient investors): Krystal Biotech (NASDAQ: KRYS) and Editas Medicine (NASDAQ: EDIT). Krystal Biotech develops gene-editing therapies for rare skin diseases.

Yahoo | February 2, 2022

BofA Bullish On This Gene Therapy Biotech Transitioning Into A Commercial Enterprise

Krystal Biotech Inc (NASDAQ: KRYS ) shares have potential to nearly double from current levels, according to an analyst at BofA Securities. The Krystal Biotech Analyst: Geoff Meacham initiated coverage of Krystal Biotech shares with a Buy rating and a $110 price target. The Krystal Biotech Thesis: Krystal Biotech, a clinical-stage biotech, is developing differentiated HSV-based gene therapies for inherited dermatological and respiratory diseases, Meacham said in a note. Krystal differentiates itself due to its ability to package large transgenes and re-dose their gene therapies in a transient manner, which significantly increases the breadth of potential applications, the analyst said. Nominated therapeutic areas include cystic fibrosis, Full story available on Benzinga.com

Benzinga | January 18, 2022

Read More 'KRYS' Stories Here

KRYS Price Returns

1-mo 18.55%
3-mo 9.88%
6-mo 16.37%
1-year 12.26%
3-year 76.73%
5-year N/A
YTD 6.82%
2021 16.58%
2020 8.34%
2019 166.51%
2018 97.53%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7693 seconds.